MedTrace Logo

Clinical, Histological and In-depth Molecular Characterization as Well as Experimental Models of Liver Metastasis From Patients With Breast Cancer in Order to Identify New Potential Treatment Avenues.

NCT05720676 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-02-09

No results posted yet for this study

Summary

The goal of this observational study is to learn about breast cancer liver metastasis in patients who met the following criteria:

* female;
* be ≥ 18 years of age on the day of signing informed consent;
* confirmed diagnosis of breast cancer liver metastases. Newly diagnosed patients with de-novo liver metastases are eligible;
* be planned for liver surgery.

The main questions it aims to answer are:

1. To characterize the tumour cells and their microenvironment in the liver metastases at the transcriptomic and protein single-cell level;
2. To determine the levels and patterns of immune infiltrates in liver metastases from BC patients;
3. To identify biological features associated with the histopathological growth patterns in liver metastases.
4. To create patient-derived xenografts (PDX) and organoids (PDO) from liver metastases isolated from patients with BC;
5. To perform a histopathological and molecular comparison of liver metastases, PDX and PDO isolated from the same patient

Participants will be willing and able to provide written informed consent for this study and tissue samples for research purposes.

Conditions

Sponsors & Collaborators

  • Jules Bordet Institute

    collaborator OTHER

  • Erasme University Hospital

    collaborator OTHER

  • GZA Ziekenhuizen Campus Sint-Augustinus

    collaborator OTHER

  • KU Leuven

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05720676 on ClinicalTrials.gov